Zydus Lifesciences Annual Secretarial Compliance Report for FY 2025-26

Zydus Lifesciences Limited has released its Annual Secretarial Compliance Report for the financial year ended March 31, 2026. The report confirms that the company has largely adhered to mandatory corporate governance and legal standards. While the company maintained a high level of compliance across all operational areas, it disclosed a minor procedural delay regarding the prior intimation of a board meeting, for which a ₹11,800 fine was paid to each major stock exchange.

Report Overview

The annual audit, conducted by SPANJ & Associates, reviewed the corporate filings, website disclosures, and internal policies of Zydus Lifesciences Limited for the fiscal year 2026. The assessment confirms that the company remains in alignment with all significant legal and procedural mandates required for listed entities.

Operational Compliance Highlights

The comprehensive review verified that the company is effectively managing its core governance obligations. Key areas of successful compliance include:

  • Policy Adherence: All applicable policies are updated and approved by the board.
  • Website Transparency: The company maintains a fully functional and transparent website for investor information.
  • Director Standards: All board members meet the necessary qualifications and are free from disqualification under current laws.
  • Subsidiary Governance: Proper identification and disclosure protocols for material subsidiaries are in place.
  • Performance Evaluation: Formal evaluation of the Board, its committees, and independent directors was conducted at the start of the year.

Disclosure Regarding Board Meeting Intimation

The report highlighted a specific instance of non-compliance regarding the timing of a board meeting notice. On November 6, 2025, the company held a board meeting to discuss a fund-raising proposal. The mandatory prior intimation was provided to the stock exchanges one working day in advance, rather than the required two-day notice period. This delay was attributed to a regional holiday in Mumbai, which was not observed in Ahmedabad, where the company’s registered office is situated. As a result, the company paid a fine of ₹11,800 to both the BSE and NSE, successfully resolving the matter.

Conclusion

Aside from the aforementioned procedural error, the auditors found no other instances of non-compliance. The company continues to prioritize its commitment to high standards of corporate governance and transparent reporting as it moves into the next fiscal period.

Source: BSE

Previous Article

Balaji Amines Commissioning of India’s First Dimethyl Ether (DME) Manufacturing Plant

Next Article

Strides Pharma Science Limited NCLT Approves Demerger of Arco Lab Undertakings